id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-P-0359-0007,FDA,FDA-2010-P-0359,"Attachment B - ""Product Description/Information, Surgiflo® Original, Surgicel ® Nu-Knit and Surgeicel® Fibrillar™"" - [Goodwin Procter, LLP - Citizen Petition ]",Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:30:01Z,,0,0,0900006480b138bf
FDA-2010-P-0359-0006,FDA,FDA-2010-P-0359,"Attachment A - ""Product Description/Information, Surgiflo"" - [Goodwin Procter, LLP - Citizen Petition ]",Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:29:29Z,,0,0,0900006480b13874
FDA-2010-P-0359-0009,FDA,FDA-2010-P-0359,MDR Record Analysis_Jan 2010-Mar 2022_LMG re: Supplement to Citizen Petition,Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:31:55Z,,0,0,09000064850ce930
FDA-2010-P-0359-0008,FDA,FDA-2010-P-0359,Hemostatic agents – Absorbable - Revised re: Supplement to Citizen Petition,Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:31:49Z,,0,0,09000064850ccaa4
FDA-2010-P-0359-0005,FDA,FDA-2010-P-0359,Supplement to Citizen Petition,Other,Letter(s),2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2022-05-24T00:45:13Z,,0,0,090000648508b407